

Hal K Berman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1208798/publications.pdf>

Version: 2024-02-01

18
papers

1,222
citations

1040056

9
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

3022
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. <i>Cancer Cell</i> , 2015, 27, 211-222. | 16.8 | 748 |
| 2 | Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109. | 8.2 | 211 |
| 3 | Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137. | 12.8 | 63 |
| 4 | Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. <i>Modern Pathology</i> , 2014, 27, 991-1001. | 5.5 | 41 |
| 5 | B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2015, 3, 184-195. | 3.4 | 36 |
| 6 | Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168. | 2.5 | 27 |
| 7 | Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. <i>Onc Immunology</i> , 2019, 8, e1665460. | 4.6 | 27 |
| 8 | Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. <i>Journal of Clinical Pathology</i> , 2019, 72, 120-132. | 2.0 | 20 |
| 9 | Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002. | 1.6 | 16 |
| 10 | Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122. | 2.9 | 12 |
| 11 | All is not lost: learning from 9p21 loss in cancer. <i>Trends in Immunology</i> , 2022, 43, 379-390. | 6.8 | 12 |
| 12 | Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378. | | 4 |
| 13 | Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT).. <i>Journal of Clinical Oncology</i> , 2015, 33, e11588-e11588. | 1.6 | 2 |
| 14 | Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1094-1094. | 1.6 | 2 |
| 15 | External validation of the VICex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2510-2510. | 1.6 | 1 |
| 16 | Impact of endocrine therapy in early-stage breast cancer on time to locoregional recurrence.. <i>Journal of Clinical Oncology</i> , 2013, 31, 64-64. | 1.6 | 0 |
| 17 | Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1532-1532. | 1.6 | 0 |
| 18 | Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5579-5579. | 1.6 | 0 |